Respiratory Hospitalizations Following Initiation of Nerandomilast: A Case Series

The lungs are designed to be a delicate exchange station, where oxygen slips from the air into the blood and carbon dioxide moves in the opposite direction. In some people, this delicate tissue slowly turns into thick, scarred tissue, a condition known as pulmonary fibrosis. It is a relentless process that stiffens the lungs, making every breath a struggle and leaving the body starved for oxygen. For years, doctors have had a few tools to slow this decline, but the disease often continues to worsen, and the only definitive cure remains a lung transplant. Recently, a new medication called nerandomilast was approved to help patients with this condition. It works by blocking a specific enzyme inside the body's cells, a mechanism intended to reduce the inflammation and scarring that drive the disease forward. Because this drug is new, having been on the market for less than a year, doctors are carefully watching to see how it behaves in the real world, looking for any signs that it might cause unexpected problems.

A team of researchers at the University of Texas Southwestern Medical Center recently examined the records of four patients who were prescribed this new medication. They focused on a specific window of time: the two weeks immediately after the patients started taking the drug. In all four cases, the patients ended up in the hospital with severe breathing difficulties. Three of these patients showed clear signs of an acute worsening of their lung disease, a dangerous event where the lungs suddenly become inflamed and filled with fluid, a condition doctors call an exacerbation. The fourth patient also struggled to breathe, but their situation was complicated by fluid retention in the body, making it harder to say if the lung disease itself was the sole cause of the crisis.

The first patient was a woman with a history of autoimmune disease and lung scarring. She had been stable for years until her condition began to decline. After trying other treatments that caused side effects, she started the new medication. Just one week later, she was admitted to the hospital with worsening shortness of breath and chest pain. A scan of her chest revealed new, hazy patches in her lungs that were not there before. Doctors performed a procedure to wash out a small amount of fluid from her lungs to check for infection, but the results came back negative for bacteria or fungi. Instead, the fluid contained a high number of immune cells that suggested her own body was reacting to the lung tissue. She was treated with steroids to calm the inflammation and eventually improved, but the new drug was stopped.

The second patient, a woman with unclassifiable lung scarring, had a history of frequent hospital visits. She had recently started a different medication for her lungs, but her breathing continued to get worse. Doctors added the new drug to her regimen. Within a week, she was back in the hospital with severe breathing failure, requiring high levels of oxygen to survive. Her scans showed that the hazy, inflamed areas in her lungs had grown significantly compared to images taken just three months prior. Extensive testing ruled out infections and heart failure. She responded well to intravenous steroids, and the new medication was discontinued.

The third patient was a woman with a complex autoimmune condition affecting her skin and lungs. She had been on various treatments for years, including a medication that caused stomach problems. When her lung function began to drop, the new drug was prescribed. Only three days later, she arrived at the hospital with a rapid heart rate and a sudden need for more oxygen. Her chest scan showed a marked increase in the hazy patches typical of lung inflammation. While she also had signs of fluid overload in her body, the rapid onset of symptoms shortly after starting the drug raised concerns. She was treated with steroids and diuretics to remove excess fluid, and her breathing improved, but the new medication was not continued.

The final patient was a man with a family history of lung scarring and a known exposure to mold in his home. His lung function was already very poor when he started the new medication. He had been taking a short course of steroids to prepare for the new drug. Just three days after beginning the medication, he felt his breathing deteriorate rapidly. In a clinic visit, his oxygen levels dropped dangerously low. A scan of his chest showed a dramatic increase in the hazy, inflamed areas compared to his previous scans. Because his condition was so severe, he was placed on an urgent list for a lung transplant. He received a new pair of lungs, and an examination of the removed lungs showed a mix of old scarring and fresh, acute injury to the lung tissue, consistent with a sudden flare-up of the disease.

The researchers noted that for three of the four patients, the timing and the nature of their hospitalizations fit the definition of a sudden, severe worsening of their lung disease. The fourth patient's case was more difficult to pin down because of the fluid overload, but the pattern across the group was striking. All four events happened within two weeks of starting the medication. The study does not prove that the drug caused these events, as the patients were already suffering from a progressive and dangerous disease. However, the fact that these severe reactions occurred so soon after starting the treatment suggests a possible link. The authors conclude that this pattern warrants further investigation to understand if the drug might trigger these dangerous flare-ups in some patients, ensuring that future use of the medication is as safe as possible.